http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
-
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
-
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
-
BeiGene's (BGNE) BRUKINSA Demonstrated Superior PFS Over IMBRUVICA in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
-
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
-
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
-
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
-
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
-
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
-
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
-
BeiGene Reports Third Quarter 2022 Financial Results
-
BeiGene to Present at Upcoming Investor Conferences
-
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
-
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
-
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
-
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
-
BeiGene (BGNE) Announces Positive Topline Results from Final PFS Analysis of BRUKINSA Compared to IMBRUVICA in Phase 3 CLL Trial
-
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL)
-
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
-
BeiGene (BGNE) Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
-
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
-
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
-
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
-
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
-
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
-
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
-
BeiGene Reports Second Quarter 2022 Financial Results
-
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
-
BeiGene Appoints Chan Lee as General Counsel
-
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
-
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
-
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
-
BeiGene (BGNE) Announces BRUKINSA Is Approved in 50 Markets
-
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
-
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
-
BeiGene (BGNE) Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at EHA
-
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
-
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
-
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
-
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
-
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
-
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
-
BeiGene Reports First Quarter 2022 Financial Results
-
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
-
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
-
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
-
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
-
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
-
BeiGene Introduces Global Environmental, Social, and Governance Strategy
-
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
